CTSO:NASDAQ
Cytosorbents Corp
$0.40
arrow_upward
+10.38%(+0.038) 1D
Ago 14, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa CTSO...
Buksan
$0.36
Mataas
$0.40
Mababa
$0.36
Mkt. cap
25.29M
Avg. na dami
65.29K
Dami
66.67K
Mataas nang 52-wk
$1.19
Mababa nang 52-wk
$0.35
EPS
-$0.29
Beta
1.39
Mga natitirang share
62.84M
Bilang ng mga empleyado
129
Buksan
$0.36
Mataas
$0.40
Mababa
$0.36
Mkt. cap
25.29M
Avg. na dami
65.29K
Dami
66.67K
Mataas nang 52-wk
$1.19
Mababa nang 52-wk
$0.35
EPS
-$0.29
Beta
1.39
Mga natitirang share
62.84M
Bilang ng mga empleyado
129
Profile
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Tungkol sa Cytosorbents Corp
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa